Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events

J. Alfred Witjes, Joan Palou, Mark Soloway, Donald Lamm, Maurizio Brausi, J. Roan Spermon, Raj Persad, Roger Buckley, Hideyuki Akaza, Marc Colombel, Andreas Böhle

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Context: Although intravesical therapy is an integral part of the management of non-muscle invasive bladder cancer (NMIBC), both intravesical chemotherapy and bacillus Calmette-Guérin (BCG) have potential side effects that may lead to treatment cessation and incomplete treatment courses. Objective: To provide evidence-based strategies for the prevention and management of intravesical therapy-associated adverse events. Evidence acquisition: A committee of international leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), was convened in October 2006 to review current literature surrounding adverse events associated with intravesical therapy. Following the inaugural meeting in October 2006, the IBCG met on three subsequent occasions to exchange ideas and to develop practical recommendations for the prevention and management of these adverse events. Evidence synthesis: The IBCG provided an overview of adverse events associated with BCG and intravesical chemotherapy as well as practical recommendations for the prevention and management of these side effects based on current evidence. Conclusions: Cystitis and hematuria are side effects common to both chemotherapy and BCG. Other rare complications common to both intravesical therapies include contracted bladder and ureteral obstructions. BCG-specific adverse events include granulomatous prostatitis, epididymo-orchitis, systemic BCG reactions, and allergic reactions, while side effects specific to intravesical chemotherapy include contact dermatitis, bladder calcifications, and myelosuppression. The keys to management of these adverse events are education, prevention, and awareness. Preventive strategies include instructing health care professionals about proper catheterisation techniques and instilling BCG at least 2 wk following a TURBT; if catheterisation is traumatic or the patient has a urinary tract infection, BCG instillations should be deferred for 1 wk. Furthermore, the use of prophylactic ofloxacin 200 mg given twice after BCG instillations appears to be a simple and practical method of improving BCG tolerability while maintaining its efficacy. BCG dose reduction may also be a reasonable option, particularly for those patients known to be intolerant to standard-dose BCG.

Original languageEnglish
Pages (from-to)667-674
Number of pages8
JournalEuropean Urology, Supplements
Volume7
Issue number10
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Bacillus
Urinary Bladder Neoplasms
Therapeutics
Drug Therapy
Catheterization
Urinary Bladder
Orchitis
Ureteral Obstruction
Prostatitis
Withholding Treatment
Ofloxacin
Cystitis
Contact Dermatitis
Hematuria
Urinary Tract Infections
Hypersensitivity
Delivery of Health Care
Education

Keywords

  • Bladder calcifications
  • Contact dermatitis
  • Contracted bladder
  • Cystitis
  • Epididymo-orchitis
  • Granulomatous prostatitis
  • Hematuria
  • Intravesical therapy-associated adverse events
  • Myelosuppression
  • Systemic bacillus Calmette-Guérin reactions

ASJC Scopus subject areas

  • Urology

Cite this

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events. / Witjes, J. Alfred; Palou, Joan; Soloway, Mark; Lamm, Donald; Brausi, Maurizio; Spermon, J. Roan; Persad, Raj; Buckley, Roger; Akaza, Hideyuki; Colombel, Marc; Böhle, Andreas.

In: European Urology, Supplements, Vol. 7, No. 10, 01.10.2008, p. 667-674.

Research output: Contribution to journalArticle

Witjes, JA, Palou, J, Soloway, M, Lamm, D, Brausi, M, Spermon, JR, Persad, R, Buckley, R, Akaza, H, Colombel, M & Böhle, A 2008, 'Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events', European Urology, Supplements, vol. 7, no. 10, pp. 667-674. https://doi.org/10.1016/j.eursup.2008.08.001
Witjes, J. Alfred ; Palou, Joan ; Soloway, Mark ; Lamm, Donald ; Brausi, Maurizio ; Spermon, J. Roan ; Persad, Raj ; Buckley, Roger ; Akaza, Hideyuki ; Colombel, Marc ; Böhle, Andreas. / Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events. In: European Urology, Supplements. 2008 ; Vol. 7, No. 10. pp. 667-674.
@article{f13dfa759b3a4a919d4a83189b3383ae,
title = "Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events",
abstract = "Context: Although intravesical therapy is an integral part of the management of non-muscle invasive bladder cancer (NMIBC), both intravesical chemotherapy and bacillus Calmette-Gu{\'e}rin (BCG) have potential side effects that may lead to treatment cessation and incomplete treatment courses. Objective: To provide evidence-based strategies for the prevention and management of intravesical therapy-associated adverse events. Evidence acquisition: A committee of international leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), was convened in October 2006 to review current literature surrounding adverse events associated with intravesical therapy. Following the inaugural meeting in October 2006, the IBCG met on three subsequent occasions to exchange ideas and to develop practical recommendations for the prevention and management of these adverse events. Evidence synthesis: The IBCG provided an overview of adverse events associated with BCG and intravesical chemotherapy as well as practical recommendations for the prevention and management of these side effects based on current evidence. Conclusions: Cystitis and hematuria are side effects common to both chemotherapy and BCG. Other rare complications common to both intravesical therapies include contracted bladder and ureteral obstructions. BCG-specific adverse events include granulomatous prostatitis, epididymo-orchitis, systemic BCG reactions, and allergic reactions, while side effects specific to intravesical chemotherapy include contact dermatitis, bladder calcifications, and myelosuppression. The keys to management of these adverse events are education, prevention, and awareness. Preventive strategies include instructing health care professionals about proper catheterisation techniques and instilling BCG at least 2 wk following a TURBT; if catheterisation is traumatic or the patient has a urinary tract infection, BCG instillations should be deferred for 1 wk. Furthermore, the use of prophylactic ofloxacin 200 mg given twice after BCG instillations appears to be a simple and practical method of improving BCG tolerability while maintaining its efficacy. BCG dose reduction may also be a reasonable option, particularly for those patients known to be intolerant to standard-dose BCG.",
keywords = "Bladder calcifications, Contact dermatitis, Contracted bladder, Cystitis, Epididymo-orchitis, Granulomatous prostatitis, Hematuria, Intravesical therapy-associated adverse events, Myelosuppression, Systemic bacillus Calmette-Gu{\'e}rin reactions",
author = "Witjes, {J. Alfred} and Joan Palou and Mark Soloway and Donald Lamm and Maurizio Brausi and Spermon, {J. Roan} and Raj Persad and Roger Buckley and Hideyuki Akaza and Marc Colombel and Andreas B{\"o}hle",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.eursup.2008.08.001",
language = "English",
volume = "7",
pages = "667--674",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events

AU - Witjes, J. Alfred

AU - Palou, Joan

AU - Soloway, Mark

AU - Lamm, Donald

AU - Brausi, Maurizio

AU - Spermon, J. Roan

AU - Persad, Raj

AU - Buckley, Roger

AU - Akaza, Hideyuki

AU - Colombel, Marc

AU - Böhle, Andreas

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Context: Although intravesical therapy is an integral part of the management of non-muscle invasive bladder cancer (NMIBC), both intravesical chemotherapy and bacillus Calmette-Guérin (BCG) have potential side effects that may lead to treatment cessation and incomplete treatment courses. Objective: To provide evidence-based strategies for the prevention and management of intravesical therapy-associated adverse events. Evidence acquisition: A committee of international leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), was convened in October 2006 to review current literature surrounding adverse events associated with intravesical therapy. Following the inaugural meeting in October 2006, the IBCG met on three subsequent occasions to exchange ideas and to develop practical recommendations for the prevention and management of these adverse events. Evidence synthesis: The IBCG provided an overview of adverse events associated with BCG and intravesical chemotherapy as well as practical recommendations for the prevention and management of these side effects based on current evidence. Conclusions: Cystitis and hematuria are side effects common to both chemotherapy and BCG. Other rare complications common to both intravesical therapies include contracted bladder and ureteral obstructions. BCG-specific adverse events include granulomatous prostatitis, epididymo-orchitis, systemic BCG reactions, and allergic reactions, while side effects specific to intravesical chemotherapy include contact dermatitis, bladder calcifications, and myelosuppression. The keys to management of these adverse events are education, prevention, and awareness. Preventive strategies include instructing health care professionals about proper catheterisation techniques and instilling BCG at least 2 wk following a TURBT; if catheterisation is traumatic or the patient has a urinary tract infection, BCG instillations should be deferred for 1 wk. Furthermore, the use of prophylactic ofloxacin 200 mg given twice after BCG instillations appears to be a simple and practical method of improving BCG tolerability while maintaining its efficacy. BCG dose reduction may also be a reasonable option, particularly for those patients known to be intolerant to standard-dose BCG.

AB - Context: Although intravesical therapy is an integral part of the management of non-muscle invasive bladder cancer (NMIBC), both intravesical chemotherapy and bacillus Calmette-Guérin (BCG) have potential side effects that may lead to treatment cessation and incomplete treatment courses. Objective: To provide evidence-based strategies for the prevention and management of intravesical therapy-associated adverse events. Evidence acquisition: A committee of international leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), was convened in October 2006 to review current literature surrounding adverse events associated with intravesical therapy. Following the inaugural meeting in October 2006, the IBCG met on three subsequent occasions to exchange ideas and to develop practical recommendations for the prevention and management of these adverse events. Evidence synthesis: The IBCG provided an overview of adverse events associated with BCG and intravesical chemotherapy as well as practical recommendations for the prevention and management of these side effects based on current evidence. Conclusions: Cystitis and hematuria are side effects common to both chemotherapy and BCG. Other rare complications common to both intravesical therapies include contracted bladder and ureteral obstructions. BCG-specific adverse events include granulomatous prostatitis, epididymo-orchitis, systemic BCG reactions, and allergic reactions, while side effects specific to intravesical chemotherapy include contact dermatitis, bladder calcifications, and myelosuppression. The keys to management of these adverse events are education, prevention, and awareness. Preventive strategies include instructing health care professionals about proper catheterisation techniques and instilling BCG at least 2 wk following a TURBT; if catheterisation is traumatic or the patient has a urinary tract infection, BCG instillations should be deferred for 1 wk. Furthermore, the use of prophylactic ofloxacin 200 mg given twice after BCG instillations appears to be a simple and practical method of improving BCG tolerability while maintaining its efficacy. BCG dose reduction may also be a reasonable option, particularly for those patients known to be intolerant to standard-dose BCG.

KW - Bladder calcifications

KW - Contact dermatitis

KW - Contracted bladder

KW - Cystitis

KW - Epididymo-orchitis

KW - Granulomatous prostatitis

KW - Hematuria

KW - Intravesical therapy-associated adverse events

KW - Myelosuppression

KW - Systemic bacillus Calmette-Guérin reactions

UR - http://www.scopus.com/inward/record.url?scp=51349114054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349114054&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2008.08.001

DO - 10.1016/j.eursup.2008.08.001

M3 - Article

AN - SCOPUS:51349114054

VL - 7

SP - 667

EP - 674

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 10

ER -